Form 4: GoodRx Director Acquires Shares via RSU Vesting

GoodRx Holdings, Inc. Director Douglas Joseph Hirsch acquired 20,521 Class A Common Stock shares through the vesting of restricted stock units.

Summary

• Douglas Joseph Hirsch, a Director of GoodRx Holdings, Inc. (GDRX), acquired 20,521 shares of Class A Common Stock.
• This acquisition resulted from the vesting of restricted stock units (RSUs) on October 26, 2025.
• Following this transaction, Douglas Joseph Hirsch directly holds 231,909 shares of Class A Common Stock.
• He also indirectly holds 2,632,721 shares through the DH 2024-2 GRAT, where he serves as sole trustee and annuitant.
• An additional 2,632,721 shares are held indirectly by the CH 2024-2 GRAT, for which Mr. Hirsch disclaims beneficial ownership.

Sentiment

Score: 6

Explanation: The transaction is a routine RSU vesting, indicating continued equity compensation for a director. While not a direct 'buy' decision, it increases insider ownership, which can be seen as a minor positive for alignment. The disclaimed beneficial ownership for one GRAT adds a slight nuance but doesn't significantly alter the overall neutral-to-slightly-positive sentiment of a routine vesting.

Positives

• Director Douglas Joseph Hirsch increased his direct beneficial ownership of Class A Common Stock by 20,521 shares through RSU vesting, aligning his interests with shareholders.

Future Outlook

The restricted stock unit award vests as to one-third of the shares underlying the award on each of the first three anniversaries of the grant date, beginning on October 26, 2025, subject to continued service.

Industry Context

This filing is a routine insider transaction, common for publicly traded companies where executives and directors receive equity compensation. It reflects the vesting schedule of previously granted restricted stock units, a standard practice in executive compensation across various industries.

Comparison to Industry Standards

• The vesting of restricted stock units and subsequent acquisition of shares by a director is a standard component of executive compensation packages in the technology and healthcare sectors, aligning management interests with shareholder value.
• This type of equity award structure is widely used by companies comparable to GoodRx, such as Teladoc Health (TDOC) or Amwell (AMWL), to incentivize long-term performance and retention.

Related Party Transactions

• Shares held indirectly by CH 2024-2 GRAT, where Chona Hirsch (Reporting Person's spouse) serves as sole trustee and annuitant. Douglas Joseph Hirsch disclaims beneficial ownership of these shares.
• Shares held indirectly by DH 2024-2 GRAT, where Douglas Joseph Hirsch serves as sole trustee and sole annuitant.

Stakeholder Impact

• Shareholders: Increased direct ownership by a director may signal continued alignment of interests.
• Employees: Routine equity compensation events like RSU vesting are standard and generally have no direct impact on employees beyond the recipient.

Next Steps

• Future vesting events for the remaining restricted stock units will occur on the second and third anniversaries of the grant date (October 26, 2025).

Key Dates

Recommendation

This Form 4 filing reports a routine insider transaction involving the vesting of restricted stock units and the subsequent acquisition of shares by a director. It does not provide new financial performance data, strategic shifts, or material events that would warrant a change in investment recommendation. The increase in direct insider ownership is a minor positive for alignment but is not significant enough to alter the fundamental investment thesis for GoodRx Holdings, Inc. Therefore, a 'hold' recommendation is appropriate, maintaining existing positions based on broader company fundamentals and market conditions rather than this specific insider transaction.

Keywords

GoodRx Holdings, GDRX, Douglas Joseph Hirsch, Form 4, Insider Transaction, Restricted Stock Unit, RSU Vesting, Class A Common Stock, Director Ownership